

Familial Breast and Ovarian Cancer

Genetics, Screening and Management

This book surveys the profound and far-reaching ramifications that have arisen from the very significant advances in our understanding of the genetic basis of familial breast and ovarian cancer. Written by international experts from Europe and North America, it provides the busy clinician with a contemporary and wide-ranging guide to the latest developments in the diagnosis, genetics, screening, prevention and management of familial breast cancer. In this rapidly advancing field, this book provides an unrivalled source of information, including sections on ethical and insurance issues and the different cultural aspects of breast cancer. The use of recently devised cancer genetics clinics and different referral criteria and patterns to these clinics are also detailed. This accessible book will be of immense value to all clinical geneticists, oncologists and healthcare professionals involved in screening and counselling programmes.



Familial Breast and Ovarian Cancer

Genetics, Screening and Management

Edited by

Patrick J. Morrison

Belfast City Hospital Trust, Belfast, UK

Shirley V. Hodgson

Guy's Hospital, London, UK

and

Neva E. Haites

University of Aberdeen, Aberdeen, UK





PUBLISHED BY THE PRESS SYNDICATE OF THE UNIVERSITY OF CAMBRIDGE The Pitt Building, Trumpington Street, Cambridge, United Kingdom

CAMBRIDGE UNIVERSITY PRESS
The Edinburgh Building, Cambridge CB2 2RU, UK
40 West 20th Street, New York, NY 10011-4211, USA
477 Williamstown Road, Port Melbourne, VIC 3207, Australia
Ruiz de Alarcón 13, 28014 Madrid, Spain
Dock House, The Waterfront, Cape Town 8001, South Africa

http://www.cambridge.org

© Cambridge University Press 2002

This book is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2002

Printed in the United Kingdom at the University Press, Cambridge

Typeface Minion 10.5/14pt System Poltype® [VN]

A catalogue record for this book is available from the British Library

Library of Congress Cataloguing in Publication data

Familial breast and ovarian cancer: genetics, screening, and management / [edited by] Patrick J. Morrison, Shirley V. Hodgson, Neva E. Haites.

p. ; cm.

Includes bibliographical references and index.

ISBN 0 521 80373 X

- 1. Breast Cancer. 2. Breast Cancer Genetic aspects. 3. Ovaries Cancer.
- 4. Ovaries Cancer Genetic aspects. I. Morrison, Patrick J. (Patrick John), 1963– II. Hodgson, S. V.

III. Haites, Neva E. (Neva Elizabeth), 1947-

[DNLM: 1. Breast Neoplasms – genetics. 2. Ovarian Neoplasms – genetics. WP 870 F198 2002]

RC280.B8 F355 2002

616.99'449-dc21 2002025937

ISBN 0 521 80373 X hardback



To all of the families with hereditary cancer who have worked with us to begin to understand the problem, and for their patience while we search for the answers.



Contents

	List of contributors	ix
	Foreword by Helena Kennedy	xiii
	Preface	XV
Part 1	Molecular biology and natural history	1
1	Introduction Patrick J. Morrison, Shirley V. Hodgson and Neva E. Haites	3
2	Overview of the clinical genetics of breast cancer Neva Haites and Helen Gregory	6
3	Cowden syndrome and related disorders Charis Eng	22
4	Overview of the clinical genetics of ovarian cancer Pierre O. Chappuis and William D. Foulkes	43
5	Ovarian and breast cancer as part of hereditary non-polyposis colorectal cancer (HNPCC) and other hereditary colorectal cancer syndromes H. F. A. Vasen and M. A. Nooy	73
6	The natural history of hereditary breast cancer Pierre O. Chappuis, Dominique Stoppa-Lyonnet, Bernard Asselain and William D. Foulkes	81
7	Pathology of the breast and ovary in mutation carriers Sunil R. Lakhani and Adrienne M. Flanagan	108
8	Risk estimation for familial breast and ovarian cancer Jenny Chang-Claude and Heiko Becher	125
Part 2	Screening	141
9	Developing a cancer genetics service: a Welsh model Jonathon Gray	143
vii		



viii	List of contents	
10	Referral criteria for cancer genetics clinics Diana M. Eccles	157
11	Guidelines for the development of cancer genetics services Neva E. Haites, Shirley V. Hodgson and the Scottish Office Working Group on Cancer Genet	166 ics
12	Cultural and educational aspects influencing the development of cancer genetics services in different European countries Shirley V. Hodgson	194
13	Screening, detection and survival patterns of breast and other cancers in high-risk families Pål Møller and C. Michael Steel	204
14	Screening for familial ovarian cancer Barnaby Rufford, Usha Menon and Ian Jacobs	220
Part 3	Management	235
15	Management of <i>BRCA1/2</i> mutation carriers Pierre O. Chappuis and William D. Foulkes	237
16	Management of familial ovarian cancer Dirk Brinkmann and Ian Jacobs	275
17	Prophylactic mastectomy in mutation carriers D. G. R. Evans, F. I. Lalloo and A. D. Baildam	286
18	Psychosocial aspects of genetic counselling for breast and ovarian cancer Alison Bish and Steven Sutton	295
19	BRCA1/2 testing: uptake and its measurement Lucy Brooks, Andrew Shenton, F. I. Lalloo and D. G. R. Evans	306
20	Breast cancer genetics: ethical, social and insurance issues Patrick J. Morrison and C. Michael Steel	339
21	Gene therapy for breast and ovarian cancer Richard Kennedy and Patrick G. Johnston	372
22	Future directions Patrick J. Morrison, Shirley V. Hodgson and Neva E. Haites	384
	Index	393



Contributors

Bernard Asselain

Department of Biostatistics, Institut Curie, Paris, France

A. D. Baildam

Department of Surgery, Withington Hospital, Manchester, UK

Heiko Becher

University of Heidelberg,
Department of Tropical Hygiene
and Public Health,
Im Neuenheimer Feld 324,
69120 Heidelberg,
Germany

Alison Bish

Psychosocial Oncology Group, Cancer Research UK, London, UK

Dirk Brinkmann

Gynaecological Oncology Unit, St Bartholomew's and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, UK

Lucy Brooks

Department of Medical Genetics, St Mary's Hospital, Manchester, UK

Jenny Chang-Claude

Division of Epidemiology, German Cancer Research Centre, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

Pierre O. Chappuis

Room L10–120, Montreal General Hospital, 1650 Cedar Ave, Montreal, Quebec, Canada

Diana M. Eccles

Department of Human Genetics, Princess Anne Hospital, Southampton, UK

Charis Eng

Clinical Cancer Genetics Program, Ohio State University, Human Cancer Genetics, 420 West 12th Avenue, Suite 690 TMRF Columbus, Ohio, USA

ix



x List of contributors

D. G. R. Evans

Department of Medical Genetics, St Mary's Hospital, Hathersage Road, Manchester, UK

Adrienne M. Flanagan

Department of Histopathology, Royal Free and University College Medical School, Rockefeller Building, University Street, London, UK

William D. Foulkes

Division of Medical Genetics, Montreal General Hospital, 1650 Cedar Ave, Montreal, Quebec, Canada

Jonathon Gray

Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, UK

Helen Gregory

Department of Medical Genetics, Grampian University Hospitals Trust, Foresterhill, Aberdeen, UK

Neva E. Haites

Department of Medical Genetics, University of Aberdeen, Foresterhill, Aberdeen, UK

Shirley V. Hodgson

Division of Medical and Molecular Genetics, Guy's Hospital, London Bridge, London, UK

Ian Jacobs

Department of Obstetrics and Gynaecology St Bartholomew's and The Royal London School of Medicine and Dentistry, London, UK

Patrick G. Johnston

Department of Oncology, Belfast City Hospital Trust, Belfast, UK

Richard Kennedy

Department of Oncology, Belfast City Hospital Trust, Belfast, UK

Sunil R. Lakhani

The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London, UK

F. I. Lalloo

Department of Medical Genetics, St Mary's Hospital, Hathersage Road, Manchester, UK

Usha Menon

Gynaecological Oncology Unit, St Bartholomew's and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, UK



xi List of contributors

Pål Møller

Unit of Medical Genetics, The Norwegian Radium Hospital, N-0310 Oslo, Norway

Patrick J. Morrison

Department of Medical Genetics, Belfast City Hospital Trust, Belfast, UK

M. A. Nooy

Leiden University Medical Centre, Rijnsburgerweg 10, Poortgebouw Zuid, 2333 AA Leiden, The Netherlands

Barnaby Rufford

Gynaecological Oncology Unit, St Bartholomew's and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, UK

Andrew Shenton

Department of Medical Genetics, St Mary's Hospital, Manchester, UK

C. Michael Steel

School of Biological and Medical Sciences, Bute Medical Building, St Andrews, Fife, Scotland

Dominique Stoppa-Lyonnet

Unité de Génétique Oncologique Institut Curie, Section Médicale, 26 Rue d'Ulm, 75231 Paris, France

Steven Sutton

Health Behaviour Unit, Epidemiology and Public Health, Brook House, 2–16 Torrington Place, London, UK

H. F. A. Vasen

Netherlands Foundation for the Detection of Hereditary Tumours, Rijnsburgerweg 10, Poortgebouw Zuid, 2333 AA Leiden, The Netherlands



Foreword

I am very pleased to have been asked to write the Foreword to this important and timely book. As Chair of the Human Genetics Commission I am only too aware of the impact of familial breast cancer, or indeed many other familial cancers, on our work.

The issues raised by an increased understanding of the genetics of breast cancer have formed part of our thinking on how to deal with issues of privacy and confidentiality, such as the provision of genetic information to family members. Moving beyond the clinical, we have also considered some of the issues concerning patenting of gene sequences, taking as one example the continuing debate about the BRCA1 and BRCA2 gene patents. In addition, we have considered familial breast cancer as one of several conditions on the radar of insurance companies before underwriting life or health insurance.

I am therefore pleased to see that a fellow member of the Human Genetics Commission, Professor Patrick Morrison, and his colleagues have so carefully and clearly set out many of these important issues in this book. I hope that it will be widely read by clinicians and those responsible for policy in all of these areas and that they will take note of the important messages herein.

May 2002

Baroness Helena Kennedy QC

xiii



Preface

Cancer genetics is a new field where medical knowledge is developing rapidly, and there is a continuing need to assess the implications of new research into the genetic aspects of breast and ovarian cancer for clinical management.

Clearly, many individuals have a family history of cancer, but only a small proportion have inherited genes conferring a high risk of developing specific cancers. The development of services to identify individuals at high risk for genetic assessment/testing and management, and to offer those at moderately increased risk appropriate surveillance and follow-up for cancer, is a major organizational challenge which must be shared between clinicians at all levels – from primary care to the specialist geneticist.

Because this field is developing so rapidly, there are scanty up-to-date, concise and accessible sources of information to which interested professionals (whether clinical geneticists, surgeons, oncologists, psychologists or other professionals) can turn. This book has been written to address this.

It is divided into three parts. Part 1 deals with summaries of the molecular biology and natural history of hereditary breast and ovarian cancer. Part 2 examines current screening recommendations, how services have been set up, the characteristics of patients referred, and how services differ in different cultures. Part 3 deals with management of breast and ovarian cancer in mutation carriers and those at high risk, and also includes chapters on ethical, social and insurance issues, psychosocial aspects, and preventative surgery.

We hope this volume will be regularly updated and will be of value to all those involved in cancer genetic screening, counselling and management programmes.

2002 Patrick J. Morrison

ΧV



Acknowledgements

We are particularly grateful to our secretaries, Joanne Hazlett, Elizabeth Manners and Liza Young, for reformatting and typing parts of the manuscript, and to our families for tolerating us beyond the bounds of reasonable duty, during the writing of this book.